A common phosphotyrosine signature for the Bcr-Abl kinase

The Bcr-Abl fusion kinase drives oncogenesis in chronic myeloid leukemia (CML). CML patients are currently treated with the Abl tyrosine kinase inhibitor imatinib, which is effective in early stages of the disease. However, resistance to imatinib arises in later disease stages primarily because of a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Goss, Valerie L., Lee, Kimberly A., Moritz, Albrecht, Nardone, Julie, Spek, Erik J., MacNeill, Joan, Rush, John, Comb, Michael J., Polakiewicz, Roberto D.
Formato: Artigo
Lenguaje:Inglês
Publicado: The American Society of Hematology 2006
Materias:
Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895816/
https://ncbi.nlm.nih.gov/pubmed/16497976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-08-3399
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares